News

NGM621 is a monoclonal antibody product candidate engineered to potently inhibit complement C3 for the treatment of patients with geographic atrophy secondary to age-related macular degeneration.

The company noted that the study was the first to evaluate whether AI software can accurately detect more-than-mild diabetic retinopathy using a single image per eye, obtained from either a desktop or handheld retinal camera.

The 3-month study will assess the safety and ocular hypotensive efficacy of TC-002 ophthalmic solution.

The FDA has approved the first generic of cyclosporine ophthalmic emulsion (Restasis; Allergan) 0.05% single-use vials of eye drops to increase tear production in patients with dry eye disease.

Researchers at the University of Arizona Health Sciences will use a $1.6 million National Eye Institute grant to study age-related lens cell changes that can lead to cataracts.

According to investigators, the implant can provide a sustained infusion of drug to the retina

Preeya Gupta, MD, walks through her four pearls for successful corneal collagen cross-linking, including handling patient expectations, managing the epithelial cells and preventing infectious keratitis.

A team of investigators has conducted ocular pharmacokinetic studies, including metabolism, providing valuable information for ocular drug development.

A team of investigators examined the association between COVID-19 transmissibility and elapsed time since infection, and found that SARS-CoV-2 may still be transmissible 10 days post-infection.

The company is expecting topline data in April from Saturn-2, the second Phase 3 pivotal trial of TP-03, with NDA submission on track for this year.

The future of this age-related condition is bright and in focus.

According to the companies, a social media initiative will include donation to Prevent Blindness’ Sight-Saving Fund.

The GMOPC was established in February 2020 at an inaugural meeting in Los Angeles, California, as an investigator-initiated clinical research study, with Heidelberg Engineering as an industry partner.

A new treatment option may increase basal tear production in patients.

The university recently launched its Center for Neuronal Longevity, which brings together a multidisciplinary team to address unmet needs in vision loss and other neurological diseases.

Spect’s mobile device will enable providers to conduct critical eye screenings anywhere in a matter of minutes.

New routes of therapeutic administration are paving the way for innovative applications.

Investigators are searching for a link between TIAs and changes in the back of the eye.

Faricimab is the first and only FDA-approved medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Joshua Mali, MD, shares how the FDA-approved faricimab-svoa (Vabysmo, Genentech) will change the treatment landscape for wet AMD and DME.

With the addition of 7 new therapeutics, Théa will expand its presence in the U.S. market.

The new variant is described as a "subvariant" of the omicron variant and is closely related to omicron, though it has some different mutations.

Researchers collected data on COVID-19 symptoms via online surveys from in excess of 1 million 23andMe participants who self-reported their COVID-19 symptoms.

A team of investigators at the University of California, Irvine have found that inhibiting ceramide accumulation in retina protects photoreceptors improves vision

A team of investigators at the RIKEN Center for Biosystems Dynamics Research in Japan have used a genetic modification to improve human-derived retina transplants grown in the lab.

The study reviews the outcomes following penetrating, closed trauma–related injuries.

The historic eye institute celebrates six decades of leadership in eye care research, education and clinical practice.

Organization makes a commitment to expand translational research acceleration program and fund career development award.